Our resource hub is home to a wealth of articles, stories and videos about managing and living with type 1 diabetes.
Place your order for our free information packs that support adults and children who have been recently diagnosed.
Our researchers are working on different ways to develop a cure for type 1 diabetes - from growing insulin-producing beta cells in labs to hacking the immune system.
Learn about the technologies that can deliver insulin automatically when needed. And discover the next generation of insulins that are currently being developed.
You could win a cash prize of up to £25,000 when you play the Breakthrough T1D lottery. As well as the chance to win great prizes, you’ll also help fund our research to find a cure for type 1 diabetes.
Choose from a selection of modern and traditional designs in single or twin packs to support type 1 diabetes research this Christmas. Shop online and get fast delivery.
The announcement is the biggest treatment breakthrough for type 1 diabetes since the discovery of insulin.
This World Diabetes Day, we’re inviting you to celebrate by wearing your most joyful, whimsical and downright wonderful outfits.
We provide a wealth of information and free resources to help you support and empower your patients or students.
Take our free course for schools to learn more about supporting pupils with type 1 diabetes in educational settings.
JDRF has now rebranded to Breakthrough T1D. Our name has changed, our mission has not.
Home > About Breakthrough T1D UK & our impact > Our research > Information for researchers > Current research funding opportunities > International Breakthrough T1D funding opportunities
We offer a wide range of funding schemes for researchers in the field of type 1 diabetes and its associated complications, including Strategic Research Agreements, Industry Discovery and Development Partnerships, Innovative Grants and conference grants. We also offer training grants including postdoctoral fellowships, advanced postdoctoral fellowships, career development awards, early-career patient-orientated diabetes research awards and psychology fellowship awards.
The following Breakthrough T1D funding opportunities are administered by our central office in New York. Read our guidance on applying for Breakthrough T1D funding for more information about the application process.
This funding opportunity aims to increase capacity in type 1 diabetes related clinical psychology and type 1 diabetes related psychology research. The applicant is required to work with a mentor who can provide a training environment conducive to a career in type 1 diabetes-relevant psychosocial research. At the time of award activation, the applicant must have a doctoral degree (PhD, PsyD, MD), or an equivalent from an accredited institution and must not be simultaneously serving an internship or residency.
Read more about the FY25 Breakthrough T1D Diabetes Psychology Fellowship Programme call and how to apply.
This award provides seed funding for highly innovative, high-risk-high-reward research with significant potential to accelerate the mission of Breakthrough T1D. Proposals should address key outstanding questions and have the potential to lead to a challenge or a change in the current paradigm or conventional wisdom and/or lead to a groundbreaking discovery. Preliminary data is not required in the proposal, but the underlying concept, premise or hypothesis must be plausible and testable, and the proposal must be focused with a well-defined goal that is achievable within the timeframe and amount of the award.
Read more about the FY25 Innovative Award call and how to apply.
The goal of this funding opportunity is to target metabolic imbalances to improve glucometabolic outcomes in people with established type 1 diabetes (T1D). This funding opportunity will prioritise T1D clinical trials evaluating therapies either approved or in development for metabolic diseases such as T2D, obesity, and MAFLD. This program will award grants for clinical studies of up to $2,000,000 over 3 years.
Read more about the Clinical Trials Advancing Metabolic Therapies for T1D call and how to apply.
Funding for single or multiple investigators to address critical gaps and challenges and potential breakthroughs in type 1 diabetes research. The Strategic Research Agreement (SRA) is a partnership between researchers and Breakthrough T1D scientists to help address roadblocks and accelerate Breakthrough T1D’s mission through support of cutting-edge scientific investigation.
Read more about the Strategic Research Agreement and how to submit your project Concept in the Breakthrough T1D Grant Handbook.
The next SRA deadline after this will be 6 May 2025 with a LOI status notification (contact by Breakthrough T1D staff for further project development) of 17 June 2025.
We accept and review applications for funding opportunities in this section throughout the year.
Our industry partnerships aim to promote for-profit interest in Breakthrough T1D’s mission to find a cure for type 1 diabetes and its complications, focusing on a priority area within our mission. IDDP provides a mechanism and opportunity for Breakthrough T1D to foster long-term collaborative relationships with industry, taking promising type 1 diabetes research through discovery and development and toward commercialisation.
This funding opportunity is aimed at biotechnology and pharmaceutical companies or other public or private for-profit organisations. We encourage applications from companies proposing collaboration with academic researchers.
For more information about this opportunity, including current and past partnerships, please visit our Industry Research Partnerships page.
We offer financial support for scientific meetings, conferences, and workshops relevant to our mission of eradicating type 1 diabetes and its effects on people. Funding is provided for organisation and delivery of an event and does not provide individual support to an applicant for conference attendance.
You should submit your conference grant application three to six months prior to your proposed meeting date. Read more about our conference grants including eligibility criteria and how to apply in the Breakthrough T1D Grant Handbook.
These funding opportunities below have now closed but give you an idea of the type of research topics Breakthrough T1D funds. You can also find details of key dates for when you will hear whether your application has been approved and when we expect the funded projects to start.
The goal of this call is to invite applications that propose clinical trials to test small molecules, biologics, and combination therapies to delay, halt, or reverse the progression of T1D.
The proposals should be aimed at the clinical assessment of novel or untested disease-modifying therapies, or combinations of molecules that have shown preliminary clinical efficacy as single agents, with the potential to delay, halt, or reverse the progression of disease in individuals in Stage 3 of disease.
LOI’s can be submitted to Breakthrough T1D’s Strategic Research Agreement (SRA) or Industry Discovery and Development Partnership (IDDP) grant mechanisms. Please note that for IDDP LOI’s, applicants are required to contact the Breakthrough T1D scientific contact below prior to submitting an LOI. For more information on these mechanisms, please refer to the Breakthrough T1D Grant Handbook.
Applicants may request budgets of up to $1.5M per year, for up to 4 years. Consideration of budgets or timelines that exceed these guidelines must be discussed with Breakthrough T1D staff prior to LOI submission.
An informational webinar will be held on Wednesday August 28, 2024 at 7:00pm BST to provide further information on this opportunity.
Read more about the Accelerating clinical trials evaluating disease-modifying therapies for T1D call
The goal of this funding opportunity is to accelerate research and development of next generation beta cell replacement therapies for type 1 diabetes (T1D) by leveraging advancements in artificial intelligence and machine learning.
Letters of Intent (LOI) aimed at addressing one or more of the following gaps in T1D cell therapy research using AI/ML:
Proposals coming from multi-disciplinary teams comprised of both data scientists and expert T1D researchers will be prioritised.
Proposed budgets for projects should not exceed $750,000.00 USD (including 10% indirect costs) total costs for up to three years. Consideration of budgets or timelines that exceed these guidelines must be discussed with Breakthrough T1D staff prior to LOI submission. For more information on these mechanisms, please refer to the Breakthrough T1D Grant Handbook.
For-profit entities may apply under Breakthrough T1D’s Industry Discovery & Development Partnership (IDDP) funding mechanism. Please contact Dr. Nicholas Mamrak to discuss proposed scope and budget prior to submitting an application. Indirect costs are not permitted on IDDP applications.
Breakthrough T1D will hold an announcement introduction meeting via Zoom on September 10, 2024, from 6 pm BST to which all prospective applicants are invited. Breakthrough T1D scientists will give an overview of the goals of this initiative, explain the application process, and answer initial questions on applications.
Read more about the Artificial intelligence powered approaches for T1D cell therapy call.
The goal of this funding opportunity is to expand the understanding of mechanisms contributing to long term survival/function and immune tolerance toward islet grafts following transplantation in type 1 diabetes (T1D) using existing clinical datasets.
This initiative will award grants to academic investigators and industry partners of up to $750,000.00 over 2 years.
Breakthrough T1D will consider applications with increased scope (time and/or budget) where there is a strong justification. Interested applicants should discuss with the Breakthrough T1D scientific contact, nmamrak@breakthrought1d.org.
Breakthrough T1D will hold an announcement introduction meeting via Zoom on 20 August 2024, from 6-7 pm BST to which all prospective applicants are invited. Breakthrough T1D scientists will give an overview of the goals of this initiative, explain the application process, and answer initial questions on applications.
Read more about the Mechanisms of graft acceptance in clinical islet transplantation call.
This RFA is intended to support the development of automated insulin delivery (AID) systems, or components of an AID system, with the following features:
Applications proposing clinical trials may request up to a total of $2,000,000 over a maximum of three years; applications proposing nonclinical work may request up to $1,000,000 over a maximum of two years.
For-profit entities may apply under Breakthrough T1D’s Industry Discovery & Development Partnership (IDDP) funding mechanism.
Read more about the Development of devices and drugs for fully automated insulin delivery at meals call.
Funding for single or multiple investigators to address critical gaps and challenges and potential breakthroughs in type 1 diabetes research. The Strategic Research Agreement is a partnership between researchers and Breakthrough T1D scientists to help address roadblocks and accelerate Breakthrough T1D’s mission through support of cutting-edge scientific investigation.
Read more about the Strategic Research Agreement and how to submit your project Concept in the grant handbook.
The aim of this call is advancing our understanding of glycaemic changes during disease progression in presymptomatic individuals (Stages 1 and 2), with the potential to improve progression biomarkers and monitoring their transition to clinical diagnosis (Stage 3).
The focus of this call is the improvement of current or new metabolic risk assessment tools and their integration into clinically and commercially utilized testing platforms.
Proposed budgets for projects should not exceed $900,000.00 total costs for up to 3 years of duration.
Breakthrough T1D provides seed funding for highly innovative, high risk high reward research with significant potential to accelerate the mission of Breakthrough T1D. Proposals should address key outstanding questions and have the potential to lead to a challenge or a change in the current paradigm or conventional wisdom and/or lead to a ground breaking discovery.
Innovative grants provide one year of support for a maximum of $200,000.00 which includes 10% indirect costs.
Read more about the Innovative Awards in the grant handbook.
The goal of this funding opportunity is to accelerate the identification and validation of reagents that promote immune rebalance and the protection of beta cell function through modulating the trafficking of immune cells to the pancreatic islets.
Proposals submitted for this opportunity should describe the preclinical or clinical development of therapeutic strategies targeting the trafficking of disease-relevant immune cell populations.
This program will award grants of up to $900k over 3 years.
The funding aims to support the implementation and integration of evidence-based T1D specific behavioural and psychosocial interventions into clinical practice.
This program will award grants up to $1,500,000.00 over 4 years.
The funding aims to support the advancement of early preclinical stage hypoimmunogenic pluripotent stem cells (PSCs) for beta cell replacement in type 1 diabetes into late preclinical or pilot clinical testing.
The primary objective is to further develop established genetically modified beta/islet cells derived from PSCs with immune evasive properties through late preclinical validation, scaling, and clinical testing which will ultimately lead to type 1 diabetes therapies.
This funding call is titled Accelerating Collaborative Research in Type 1 Diabetes Etiology and Pathogenesis using Biosamples from an Observational Clinical Study. It is open to researchers anywhere in the world.
The funding aims to support collaborations with ENDIA investigators to improve understanding of the etiology and pathogenesis of type 1 diabetes during gestation and early childhood.
This call seeks new collaborators outside of the current network of ENDIA investigators to carry out research using data and biosamples from ENDIA. Relevant proposals led by investigators whose expertise is not type 1 diabetes are also encouraged.
ENDIA will provide biosamples, relevant clinical metadata and additional support. JDRF Australia and Helmsley will provide funding to cover project activities.
Our Small Grant Awards offer funding of up to £25,000 for a maximum of 12 months, for UK-based early career researchers.
Discover the opportunities for research projects funded in partnership with other organisations.
Learn more about how Breakthrough T1D can help you to involve people with lived experience in your research.